Nuvation Bio Completes Acquisition of AnHeart TherapeuticsBusiness Wire • 9 days ago
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Share to Feed
Investors eyeing a purchase of Nuvation Bio Inc (NUVB) shares, but tentative about paying the going market price of 3.50/share, might benefit from considering selling puts among the alternative...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
BTIG Research upgraded shares of Nuvation Bio (NYSE:NUVB - Free Report) from a neutral rating to a buy rating in a research note published on Tuesday, MarketBeat reports. The firm currently has $5.00...
Nuvation Bio (NYSE:NUVB Get Free Report) was upgraded by equities research analysts at Jefferies Financial Group from a hold rating to a buy rating in a research...
Nuvation Bio Inc. (NYSE:NUVB Free Report) Wedbush issued their Q1 2025 earnings per share estimates for Nuvation Bio in a research note issued on Monday, March 25th. Wedbush...
Nuvation Bio Inc. (NYSE:NUVB Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $2.65 and last traded at $2.63, with a volume of 656006 shares...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...